Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Stocks Crossing The 13 Week Moving Average <$10.01 -- Ignore unavailable to you. Want to Upgrade?

To: Wally Mastroly who wrote (1786)	5/29/1998 10:17:00 PM
From: James Strauss	Respond to of 13094

BJCT.... Said Jim O'Shea, chairman, president, and chief executive officer of Bioject: ''Our results represent a shift in our strategic focus toward building corporate alliances that we expect will create lucrative new markets for our technologies. We're making considerable progress on this front, with a number of near- and long-term prospects currently under review. In March, we strengthened our position in the home-use market with the acquisition of Vitajet, a manufacturer of personal use needle-free injectors. Furthermore, our blood glucose-monitoring project is advancing on schedule, with our first pre-clinical trial -- conducted in April -- yielding encouraging results.'' ********************************************************************** PORTLAND, Ore., April 20 /PRNewswire/ -- Bioject Medical Technologies, Inc. (Nasdaq: BJCT - news), the leading manufacturer of jet injection devices for needle-free subcutaneous and intramuscular injections, today announced that Mike Temple, 47, has been named chief financial officer of the company. Effective April 30, he will replace Peggy Miller, Bioject's current CFO. Noting Temple's nine years of experience as a chief financial officer in high-growth manufacturing companies, Jim O'Shea, chairman, president and chief executive officer said: ''Mike brings with him a wealth of financial and operational experience in a variety of business environments, including the medical technology field. His proven track record of significantly enhancing the business and financial capabilities of the companies he has served and his thorough understanding of Bioject's marketplace, make him an ideal chief financial officer for Bioject.'' Said Temple: ''Bioject is uniquely positioned for strategic, profitable growth, and I look forward to working with Jim and the other members of the Bioject team as they take the Company to the next level.'' Jim